Lysostaphin: A staphylococcal bacteriolysin with potential clinical applications

Pharmaceuticals

Volumn 3, Issue 4, 2010, Pages 1139-1161

  Bastos, Maria do Carmo de Freire ^a   Coutinho, Bruna Gonçalves ^a   Coelho, Marcus Lívio Varella ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antimicrobial peptides; Bacteriocins; Lysostaphin; Staphylococci; Staphylococcins

Indexed keywords

ANTIINFECTIVE AGENT; BACTROBAN NASAL; BETA LACTAM ANTIBIOTIC; CEFAPIRIN; LYSOSTAPHIN; METICILLIN; NAFCILLIN; NEOSPORIN; PLACEBO; PSEUDOMONIC ACID; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AORTA VALVE DISEASE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BOVINE MASTITIS; CATHETER INFECTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STABILITY; DRUG STRUCTURE; DRUG USE; EVENING DOSAGE; HUMAN; KIDNEY ABSCESS; MASTITIS; NONHUMAN; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; URTICARIA;

EID: 77952183463     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3041139     Document Type: Review

References (92)

1. Heng, N.C.K.; Wescombe, P.A., Burton, J.P.; Jack, R.W.; Tagg, J.R. The diversity of bacteriocins in Gram-positive bacteria. In Bacteriocins: Ecology and Evolution; Riley, M.A.; Chavan, M.A., Eds, Springer: New York, NY, USA, 2007; pp. 45-92.
2. Bierbaum, G.; Sahl, H.-G. Lantibiotics: mode of action, biosynthesis and bioengineering. Curr. Pharm. Biotechnol. 2009, 10, 2-18.
3. Nissen-Meyer, J.; Rogne, P.; Oppegård, C.; Haugen, H.S.; Kristiansen, P.E. Structure-function relationships of the non-lanthionine-containing peptide (class II) bacteriocins produced by Gram-positive bacteria. Curr. Pharm. Biotechnol. 2009, 10, 10-37.
4. Cotter, P.D.; Hill, C.; Ross, R.P. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 2005, 3, 777-788.
5. Gálvez, A.; Abriouel, H.; Lopez, R.L; Omar, N.B. Bacteriocin-based strategies for food preservation. Int. J. Food Microbiol. 2007, 120, 51-70.
6. Bastos, M.C.F.; Ceotto, H.; Coelho, M.L.V.; Nascimento, J.S. Staphylococcal antimicrobial peptides: relevant properties and potential biotechnological applications. Curr. Pharm. Biotechnol. 2009, 10, 38-61.
7. Euzéby, J.P. List of prokaryotic names with standing in nomenclature-Genus Staphylococcus. http://www.bacterio.cict.fr, accessed April 2010.
8. Bannerman, T.L.; Peacock, S.J. Staphylococcus, Micrococcus, and other catalase-positive cocci. In Manual of Clinical Microbiology; Murray, P.R.; Baron, E.J.; Jorgensen, J.H.; Landry, M.L.; Pfaller, M.A., Eds.; ASM Press: Washington D.C., USA, 2007; pp. 384-404.
9. Casey, A.L.; Lambert, P.A.; Elliott, T.S.J. Staphylococci. J. Antimicrob. Agents 2007, 29 (Suppl. 3), S23-S32.
10. Evans, H.L.; Saywer, R.G. Cycling chemotherapy: a promising approach to reducing the morbidity and mortality of nosocomial infections. Drugs Today 2003, 39, 733-738.
11. Rogers, K.L.; Fey, P.D.; Rupp, M.E. Coagulase-negative staphylococcal infections. Infect. Dis. Clin. N. Am. 2009, 23, 73-98.
12. Schindler, C.A.; Schuhardt, V.T. Lysostaphin: A new bacteriolytic agent for the Staphylococcus. Proc. Natl. Acad. Sci. USA 1964, 51, 414-421.
13. Ehlert, K.; Schrodr, W.; Labischinski, H. Specificities of FemA and FemB for different glycine residues: FemB cannot substitute for FemA in staphylococcal peptidoglycan pentaglycine side chain formation. J. Bacteriol. 1997, 179, 7573-7576.
14. Rohrer, S.; Ehlert, K.; Tschierske, M.; Labischinski, H.; Berger-Bächi, B. The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation. Proc. Natl. Acad. Sci. USA. 1999, 96, 9351-9356.
15. Kumar, J.K. Lysostaphin: an antistaphylococcal agent. Appl. Microbiol. Biotechnol. 2008, 80, 555-561.
16. Giesbrecht, P.; Wecke, J.; Recnicke, B. On the morphogenesis of the cell wall of staphylococci. Int. Rev. Cytol. 1976, 44, 225-318.
17. Joris, B.; Englebert, S.; Chu, C.P.; Kariyama, R.; Daneo-Moore, L.; Shockman, G.D.; Ghuysen, J.M. Modular design of the Enterococcus hirae muramidase-2 and Streptococcus autolysis. FEMS Microbiol. Lett. 1992, 91, 257-264.
18. Browder, H.P.; Zygmunt, W.A.; Young, J.R.; Tavormina, P.A. Lysostaphin: enzymatic mode of action. Biochem. Biophys. Res. Commun. 1965, 19, 383-389.
19. Trayer, H.R.; Buckley III, C.E. Molecular properties of lysostaphin, a bacteriolytic agent specific for Staphylococcus aureus. J. Biol. Chem. 1970, 245, 4842-4846.
20. Heinrich, P.; Rosenstein, R.; Bohmer, M.; Sonner, P.; Götz, F. The molecular organization of the lysostaphin gene and its sequences repeated in tandem. Mol. Gen. Genet. 1987, 209, 563-569.
21. Thumm, G.; Götz, F. Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus. Mol. Microbiol. 1997, 23, 1251-1265.
22. Simmonds, R.S.; Simpson, W.J.; Tagg, J.R. Cloning and sequence analysis of zooA, a Streptococcus zooepidemicus gene encoding a bacteriocin-like inhibitory substance having a domain structure similar to that of lysostaphin. Gene 1997, 189, 255-261.
23. Baba, T.; Schneewindt, O. Target cell specificity of a bacteriocin molecule: a C-terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus. EMBO J. 1996, 15, 4789-4797.
24. Gründling, A.; Schneewind, O. Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus. J. Bacteriol. 2006, 188, 2463-2472.
25. Recsei, P.A.; Gruss, A.D.; Novick, R.P. Cloning, sequence, and expression of the lysostaphin gene from Staphylococcus simulans. Proc. Natl. Acad. Sci. USA 1987, 84, 1127-1131.
26. Larrimore, S.A.; Clark, S.B.; Robinson, J.M.; Heath, H.E.; Sloan, G.L. Coordinate production of three exoenzymes by Staphylococcus staphylolyticus. J. Gen. Microbiol. 1982, 128, 1529-1535.
27. Heath, S.L.; Heath, H.E.; Sloan, G.L. Plasmid-encoded lysostaphin endopeptidase gene of Staphylococcus simulans biovar staphylolyticus. FEMS Microbiol. Lett. 1987, 44, 129-133.
28. Heath, H.E.; Heath, S.L.; Nitterauer, J.D.; Rose, K.E.; Sloan, G.L. Plasmid-encoded lysostaphin endopeptidase resistance of Staphylococcus simulans biovar staphylolyticus. Biochem. Biophys. Res. Commun. 1989, 160, 1106-1109.
29. Williamson, C.M.; Bramley, A.J.; Lax, A.J. Expression of the lysostaphin gene of Staphylococcus simulans in a eukaryotic system. Appl. Environ. Microbiol. 1994, 60, 771-776.
30. Mierau, I.; Leij, P.; van Swam, I.; Blommestein, B.; Floris, E.; Mond, J.; Smid, E.J. Industrial scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: The case of lysostaphin. Microb. Cell Fact. 2005, 4, 15.
31. Mierau, I.; Olieman, C.; Mond, J.; Smid, E.J. Optimization of the Lactococcus lactis nisin-controlled gene expression system NICE for industrial applications. Microb. Cell Fact. 2005, 4, 16.
32. Sugai, M.; Fujiwara, T.; Akiyama, T.; Ohara, M.; Komatsuzawa, H.; Inoue, S.; Suginaka, H. Purification and molecular characterization of glycylglycine endopeptidase produced by Staphylococcus capitis. J. Bacteriol. 1997, 179, 1193-1202.
33. Sugai, M.; Fujiwara, T.; Ohta, K.; Komatsuzawa, H.; Ohara, M.; Suginaka, H. epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus. J. Bacteriol. 1997, 179, 4311-4318.
34. King, B.F.; Biel, M.L.; Wilkinson, B.J. Facile penetration of the Staphylococcus aureus capsule by lysostaphin. Infect. Immun. 1980, 29, 892-896.
35. Schindler, C.A.; Schuhardt, V.T. Purification and properties of lysostaphin-A lytic agent for Staphylococcus aureus. Biochem. Biophys. Acta 1965, 97, 242-250.
36. Zygmunt, W.A.; Harrison, E.F.; Browder, H.P.; Tavormina, P.A. Comparative inhibition of methicillin-resistant strains of Staphylococcus aureus by lysostaphin and other antibiotics. Appl. Microbiol. 1968, 16, 1174-1178.
37. Zygmunt, W.A.; Browder, H.P.; Tavormina, P.A. Susceptibility of coagulase-negative staphylococci to lysostaphin ant other antibiotics. Appl. Microbiol. 1968, 16, 1168-1173.
38. Grüdling, A.; Schneewind, O. Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus. J. Bacteriol. 2006, 188, 2463-2472.
39. Schleifer, K.H.; Kandler, O. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol. Rev. 1972, 36, 407-477.
40. Schleifer, K.H.; Fisher, U. Description of a new species of the genus Staphylococcus: Staphylococcus carnosus. Int. J. Syst. Bacteriol. 1982, 32, 153-156.
41. Schneewindt, O.; Fowler, A.; Faull, K.F. Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Science 1995, 268, 103-106.
42. Francius, G.; Domenech, O.; Mingeot-Leclercq, M.P.; Dufrêne, Y.F. Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin. J. Bacteriol. 2008, 190, 7904-7909.
43. Patron, R.L.; Climo, M.W.; Goldstein, B.P.; Archer, G.L. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 1999, 43, 1754-1755.
44. Fimland, G.; Blingsmo, R.; Sletten, K.; Jung, G.; Nes, I.F.; Nissen-Meyer, J. New biologically active hybrid bacteriocins constructed by combining regions from various pediocin-like bacteriocins: the C-terminal region is important for determining specificity. Appl. Environ. Microbiol. 1996, 62, 3313-3318.
45. Kusuma, C.M.; Kokai-Kun, J.F. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 2005, 49, 3256-3263.
46. DeHart, H.; Heath, H.; Heath, L.; LeBlanc, P.; Sloan, G. The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus. Appl. Environ. Microbiol. 1995, 61, 1475-1479.
47. Ehlert, K.; Tschierske, M.; Mori, C.; Schöder, W., Berger-Bächi, B. Site-specific serine incorporation by Lif and Epr into positions 3 and 5 of the staphylococcal peptidoglycan interpeptide bridge. J. Bacteriol. 2000, 182, 2635-2638.
48. Robinson, J.M.; Hardman, J.K.; Sloan, G.L. Relationship between lysostaphin endopeptidase production and cell wall composition of Staphylococcus aureus. J. Bacteriol. 1979, 137, 1158-1164.
49. Klesius, P.H.; Schuhardt, V.Y. Use of lysostaphin in the isolation of highly polymerized deoxyribonucleic acid and in the taxonomy of aerobic Micrococcaceae. J. Bacteriol. 1968, 95, 739-743.
50. Geary, C.; Stevens, M. Rapide lysostaphin test to differentiate Staphylococcus and Micrococcus species. J. Clin. Microbiol. 1986, 23, 1044-1045.
51. Schaffner, W.; Melly, M.A.; Hash, J.H; Koenig, M.G. Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies. Yale J. Biol. Med. 1967, 39, 215-229.
52. Walsh, S.; Shah, A; Mood, J. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob. Agents Chemother. 2002, 47, 554-558.
53. Zygmunt, W.A.; Tavormina, P.A. Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog. Drug Res. 1972, 16, 309-333.
54. Dajcs, J.J.; Thibodeaux, B.A.; Girgis, D.O.; Shaffer, M.D.; Delvisco, S.M.; O'Callaghan, R.J. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest. Opthalmol. Visual Sci. 2002, 43, 3712-3716.
55. Harrison, F.E.; Cropp, C.B. Comparative in vitro activities of lysostaphin and other antistaphylococcal antibiotics on clinical isolates of Staphylococcus aureus. Appl. Microbiol. 1965, 13, 212-215.
56. Zygmunt, W.A.; Harrison, E.F.; Browder, H.P. Microbiological activities of lysostaphin and penicillins against bacteriophage 80/81 strains of Staphylococcus aureus. Appl. Microbiol. 1965, 13, 491-493.
57. Huber, M.M.; Huber, T.W. Susceptibility of methicillin-resistant Staphylococcus aureus to lysostaphin. J. Clin. Microbiol. 1989, 27, 1122-1124.
58. von Eiff, C.; Kokai-Kun, J.F.; Becker, K.; Peters, G. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob. Agents Chemother. 2003, 47, 3613-3615.
59. Polak, J.; Della Latta, P.; Blackburn, P. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 1993, 17, 265-270.
60. Graham, S.; Coote, P.J. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. J. Antimicrob. Chemother. 2007, 59, 759-762.
61. Harbarth, S.; Sax, H.; Gastmeier, P. The preventable proportion of nosocomial infections: an overview of published reports. J. Hosp. Infect. 2003, 54, 258-266.
62. Vuong, C.; Otto, M. Staphylococcus epidermidis infections. Microbes Infect. 2002, 4, 481-489.
63. Sader, H.S.; Jones, R.N.; Andrade-Baiocchi, S.; Biedenbach, D.J. Four-year evolution of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn. Microbiol. Infect. Dis. 2003, 44, 273-280.
64. Wu, J.A.; Kusuma, C.; Mond, J.J.; Kokai-Kun, J.F. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob. Agents Chemother. 2003, 47, 3407-3414.
65. Shah, A.; Mond, J.; Walsh, S. Lysostaphin-coated catheters eradicate Staphylococcus aureus challenge and block surface colonization. Antimicrob. Agents Chemother. 2004, 48, 2704-2707.
66. Schudhardt, V.T; Schindler, C.A. Lysostaphin therapy in mice infected with Staphylococcus aureus. J. Bacteriol. 1964, 88, 815-816.
67. Dixon, R.E.; Goodman, J.S.; Koenig, M.G. Lysostaphin: an enzymatic approach to staphylococcal disease. III. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice. Yale J. Biol. Med. 1968, 41, 62-68.
68. Harrison, E.F.; Zygmunt, W.A. Lysostaphin in experimental renal infection. J. Bacteriol. 1967, 93, 520-524.
69. Climo, M.W.; Patron, R.L.; Goldstein, B.P.; Archer, G.L. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 1998, 42, 1355-1360.
70. Kiri, N.; Archer, G.; Climo, M.W. Combinations of lysostaphin with β-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 2002, 46, 2017-2020.
71. Climo, M.W.; Ehlert, K.; Archer, G.L. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2001, 45, 1431-1437.
72. Placencia, F.X.; Kong, L.; Weisman, L.E. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin vs. vancomycin. Pediatr. Res. 2009, 65, 420-424.
73. Oluola, O.; Kong, L.; Fein, M.; Weisman, L.E. Lysostaphin in treatment of neonatal Staphylococcus aureus infection. Antimicrob. Agents Chemother. 2007, 51, 2198-2220.
74. Kokai-Kun, J.F.; Chanturiya, T.; Mond, J.J. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J. Antimicrob. Chemother. 2007, 60, 1051-1059.
75. Kokai-Kun, J.F.; Chanturiya, T.; Mond, J.J. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J. Antimicrob. Chemother. 2009, 64, 94-100.
76. Kokai-Kun, J.F.; Walsh, S.M.; Chanturiya, T.; Mond, J.J. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob. Agents Chemother. 2003, 47, 1589-1597.
77. Quickel Jr., K.E.; Selden, R.; Caldwell, J.R.; Nora, N.F.; Schaffner, W. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl. Microbiol. 1971, 22, 446-450.
78. Zhao, X.; Lacasse, P. Mammary tissue damage during bovine mastitis: causes and control. J. Anim. Sci. 2008, 86, 57-65.
79. Bradley, A.J. Bovine mastitis: an evolving disease. Vet. J. 2002, 164, 116-128.
80. Barkema, H.W.; Schukken, Y.H.; Zadoks, R.N. The role of cow, pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus mastitis. J. Dairy Sci. 2006, 89, 1877-1895.
81. Sears, P.M.; Smith, B.S.; Pollak, J.; Gusik, S.N.; Blackburn, P. Lysostaphin efficacy for treatment of Staphylococcus aureus intramammary infection. J. Dairy Sci. 1988, 71 (Suppl. 1), 244.
82. Oldham, E.R.; Daley, M.J. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic. J. Dairy Sci. 1991, 74, 4175-4182.
83. Daley, M.J.; Oldham, E.R. Lysostaphin immunogenicity of locally administered recombinant protein used in mastitis therapy. Vet. Immunol. Immunopathol. 1992, 31, 301-312.
84. Wall, R.J.; Powell, A.M.; Paape, M.J.; Kerr, D.E.; Bannerman, D.D.; Pursel, V.G.; Wells, K.D.; Talbot, N; Hawk, H.W. Genetically enhanced cows resist intramammary Staphylococcus aureus infection. Nat. Biotechnol. 2005, 23, 445-451.
85. Strandén, A.M.; Ehlert, K.; Labischinski, H.; Berger-Bächi, B. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J. Bacteriol. 1997, 179, 9-16.
86. Rohrer, S.; Berger-Bächi, B. FemABX peptidyl transferases: a link between branched-chain cell wall peptide formation and ß-lactam resistance in Gram-positive cocci. Antimicrob. Agents Chemother. 2003, 47, 837-846.
87. Guignard, B.; Entenza; J.M.; Moreillon, P. Beta-lactams against methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol. 2005, 5, 479-489.
88. Morikawa, K.; Maruyama, A.; Inose, Y.; Higashide, M.; Hayashi, H.; Ohta, T. Overexpression of sigma factor, sigma (B), urges Staphylococcus aureus to thicken the cell wall and to resist beta-lactams. Biochem. Biophys. Res. Commun. 2001, 288, 385-389.
89. Cui, L.; Murakami, H.; Kuwahara-Arai, K.; Hanaki, H.; Hiramatsu, K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 2000, 44, 2276-2285.
90. Koehl, J.L.; Muthaiyan, A.; Jayaswal, R.K.; Ehlert, K.; Labischinski, H.; Wilkinson, B.J. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2004, 48, 3749-3757.
91. Gründling, A.; Missiakas, D.M.; Schneewind, O. Staphylococcus aureus mutants with increased lysostaphin resistance. J. Bacteriol. 2006, 188, 6286-6297.
92. Kusuma, C.M.; Jadanova, A.; Chanturiya, T.; Kokai-Kun, J.F. Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob. Agents Chemother. 2007, 51, 475-482.